Human Gut Microbiota from Autism Spectrum Disorder Promote Behavioral Symptoms in Mice

Gil Sharon1,*, Nikki Jamie Cruz1, Dae-Wook Kang2,3,22, Michael J. Gandal4,5,6,7, Bo Wang1, Young-Mo Kim8, Erika M. Zink8, Cameron P. Casey8, Bryn C. Taylor9, Christiane J. Lane10, Lisa M. Bramer11, Nancy G. Iserr8, David W. Hoyt8, Cecilia Neecker12, Michael J. Sweredoski1, Annie Moradian1, Elhanan Borenstein12,13,14,15,16, Janet K. Jansson9, Rob Knight17,18,19,20, Thomas O. Metz8, Carlos Lois1, Daniel H. Geschwind4,5,6, Rosa Krajmalnik-Brown2,3,21, Sarkis K. Mazmanian1,23,*

1Division of Biology and Biological Engineering, California Institute of Technology, Pasadena, CA 91125, USA
2Biodesign Swette Center for Environmental Biotechnology, Arizona State University, Tempe, AZ 85287, USA
3Biodesign Center for Fundamental and Applied Microbiomics, Arizona State University, Tempe, AZ 85287, USA
4Center for Autism Research and Treatment, Program in Neurobehavioral Genetics, Semel Institute, University of California Los Angeles, Los Angeles, CA 90095, USA
5Department of Neurology, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA 90095, USA
6Department of Human Genetics, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA 90095, USA
7Department of Psychiatry, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA 90095, USA
8Earth and Biological Sciences Directorate, Pacific Northwest National Laboratory, Richland, WA 99352, USA.

*Correspondence: gsharon@caltech.edu and sarkis@caltech.edu.

Author Contributions

Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

CONFLICT OF INTERESTS:
D.W.K. and R.K-B. have pending/approved patent applications related to the use of FMT and/or probiotics for various conditions including ASD. G.S. and S.K.M. have filed a pending patent application for the use of specific microbes and metabolites for various neurodevelopmental conditions. S.K.M is a co-founder of Axial Biotherapeutics and member of its scientific advisory board.
Autism spectrum disorder (ASD) manifests as alterations in complex human behaviors including social communication and stereotypies. In addition to genetic risks, the gut microbiome differs between typically-developing (TD) and ASD individuals, though it remains unclear whether the microbiome contributes to symptoms. We transplanted gut microbiota from human donors with ASD or TD controls into germ-free mice, and reveal that colonization with ASD microbiota is sufficient to induce hallmark autistic behaviors. The brains of mice colonized with ASD microbiota display alternative splicing of ASD-relevant genes. Microbiome and metabolome profiles of mice harboring human microbiota predict that specific bacterial taxa and their metabolites modulate ASD behaviors. Indeed, treatment of an ASD mouse model with candidate microbial metabolites improves behavioral abnormalities and modulates neuronal excitability in the brain. We propose that the gut microbiota regulates behaviors in mice via production of neuroactive metabolites, suggesting that gut-brain connections contribute to the pathophysiology of ASD.
INTRODUCTION

Autism spectrum disorder (ASD) is a group of neurodevelopmental conditions involving altered social communication and interaction, as well as repetitive, stereotyped behaviors. The prevalence of ASD in children and adolescents is 1 in 59 individuals in the US (Baio et al., 2018), although higher rates have also been reported (Xu et al., 2018), with males affected more frequently than females. Considerable genetic research has highlighted the importance of de novo mutations, copy number variations, and rare and common variants in ASD etiology (An et al., 2018; Gandal et al., 2018; Sanders et al., 2015; de la Torre-Ubieta et al., 2016), many of which have been modeled in animals (Patel et al., 2018). In genetically predisposed individuals, various environmental factors may modify and/or trigger psychiatric conditions (Mazina et al., 2015; Schaafsma et al., 2017). A non-genetic, yet heritable (Moeller et al., 2018) contributor to human behaviors may be the gut microbiota, a community of microorganisms humans harbor in our gastrointestinal (GI) tract that impacts development and function of the immune, metabolic, and nervous systems (Cho and Blaser, 2012; Sandoval-Motta et al., 2017). Diet and other interventions that reconfigure a microbiome can alter its function, either within a host or when inherited by its offspring (Sonnenburg et al., 2016), and may modify disease symptoms in individuals when coupled with a genetic risk (Luca et al., 2017; Sampson et al., 2016). Alternatively, a “pathogenic” microbiome itself may be sufficient to trigger disease even in otherwise non-predisposed individuals (Kim et al., 2017). For example, transplant of microbiota from patients with depression, irritable bowel syndrome-associated anxiety, or schizophrenia into wild-type mice promoted indicationspecific behavioral symptoms (De Palma et al., 2017; Zheng et al., 2016, 2019).

The gut microbiota has been suggested to play a role in ASD. Gut bacterial communities differ between individuals with ASD and typically-developing (TD) controls (Coretti et al., 2018; De Angelis et al., 2013; Finegold et al., 2010; Gondalia et al., 2012; Kang et al., 2013, 2017a; Kushak et al., 2016; Liu et al., 2019; Son et al., 2015; Strati et al., 2017; Wang et al., 2018).
as well as in mouse models of ASD (Buffington et al., 2016; Coretti et al., 2017; Hsiao et al., 2013; Kim et al., 2017; Liu et al., 2018; de Theije et al., 2014). Fecal microbiome profiles are most divergent in ASD subjects with GI dysfunction, a common comorbidity of autism (Chaidez et al., 2014; Gorrindo et al., 2012). In addition, microbial-based interventions, including fecal transplantation, antibiotics, and probiotics, have shown promise in a limited number of human trials (Grimaldi et al., 2018; Kang et al., 2017b; Sandler et al., 2000). Specific gut microbes have demonstrated therapeutic potential in animal models of ASD (Buffington et al., 2016; Hsiao et al., 2013; Sgritta et al., 2018; Tabouy et al., 2018). Furthermore, changes in the microbiome often result in altered metabolic profiles, impacting the availability and diversity of nutrients and microbial metabolites (Dodd et al., 2017; Melnik et al., 2017; Sharon et al., 2014; Wikoff et al., 2009). Indeed, metabolomic analyses of serum, feces, and urine from ASD subjects have uncovered differences in various molecules compared to TD individuals, with many dysregulated compounds being of microbial origin (De Angelis et al., 2013; Kang et al., 2017a; Ming et al., 2012; Mussap et al., 2016; Wang et al., 2019). Notably, amino-acid transport and degradation differ between TD and ASD individuals (Aldred et al., 2003; Evans et al., 2008), intriguing since amino acids serve as precursors for many potent neuroactive molecules, such as classic neurotransmitters. In order to explore the contribution of the microbiota to ASD etiology, we sought to define functional contributions by the gut microbiota to behaviors associated with ASD. Herein, we report that colonization of germ-free (GF) wild-type mice with fecal microbiota from individuals with ASD was sufficient to promote core behavioral symptoms in their offspring, relative to those colonized with TD microbiota. We suggest a mechanism of action involving the production of microbial metabolites in the gut that affect brain function and regulate behavior.

RESULTS

Gut Microbiota from Individuals with ASD is Sufficient to Promote Altered Behaviors in Mice

Microbiome profiles of individuals with ASD, especially those of individuals with ASD with intestinal symptoms, are different from TD persons (De Angelis et al., 2013; Gondalia et al., 2012; Kang et al., 2013, 2017a; Son et al., 2015; Strati et al., 2017). While human studies are powerful, cross-sectional sampling after diagnosis yields associations that are unable to resolve cause-and-effect relationships, and do not inform whether gut microbiome changes are a consequence of disease (e.g., shaped by genetics, diet, GI symptoms, etc.) or if they contribute to symptoms. Accordingly, we tested whether altered human microbiota functionally promote ASD behaviors in mice. Fecal samples from human TD and ASD donors were selected based on Autism Diagnostic Observation Schedule (ADOS) (Gotham et al., 2007) and GI severity index (GSI) scores (Schneider et al., 2006) (Figure 1A–B, Table S1), and transplanted into GF wild-type mice, i.e., “humanized microbiome” mice. Donor fecal samples exhibited differences between TD and ASD samples in both α- and β-diversity within bacterial communities, as surveyed by high-throughput amplicon sequencing of the 16S rRNA gene (Figure 1C–D, Figure S1A–B). As ASD is a developmental disorder with evidence for prenatal effects (Hallmayer et al., 2011; Lyall et al., 2014), we colonized GF male and female C57BL/6J mice with TD or ASD donor
samples (recipient TD and ASD, annotated rTD and rASD, respectively), and subsequently bred these animals (Figure 1A). Adult offspring mice (offspring TD and ASD, annotated oTD and oASD) that inherited human donor microbiota were either sampled (feces, serum, brains) or behavior tested (Figure 1A). We stratified donors using the standardized ADOS (StdADOS) score for disease severity (Gotham et al., 2009) into three groups: TD, Mild-ASD (StdADOS = 4–5), or ASD (StdADOS = 6–10) (Figure 1B, Table S1). oASD mice, colonized with samples from ASD donors, displayed behavioral deficits relevant to ASD, while oMild-ASD mice behaved similar to oTD controls (Figure S2A–E). Specifically, we observed increased repetitive behavior, decreased locomotion, and decreased communication in oASD mice compared to mice colonized with samples from TD controls (oTD), as tested by marble burying (MB), open-field testing (OFT), and ultrasonic vocalization (USV), respectively. No differences in sociability were observed by a three-chamber sociability test (Figure S2B). These core features of ASD were not the result of anxiety or other locomotion deficits, as colonized mice spent the same amount of time in the center of an open-field arena and male mice traveled similar distances (Figures S2C–D).

Further in-depth studies were performed on a representative subset of fecal samples from three TD and five ASD donors (Figure 1B, in bold). Mice colonized with fecal samples from these donors were also behaviorally examined by the direct social interaction test (DSI), a more sensitive sociability assay. oASD mice “humanized” with fecal microbiota from ASD donors showed increased repetitive behavior, decreased sociability, and decreased locomotion compared to mice colonized with samples from TD controls (Figures 1E–G). Behavioral changes induced by ASD microbiota were more pronounced in male mice than in females (Figures S2A′–D′, S2F–G). Conversely, female oASD mice traveled shorter distances than oTD females in OFT (Figures S2C′, S2H). However, it is unknown whether this male bias was a true effect or an inherent result of our experimental design, using only human male donor samples in this study. Future studies comparing effects of samples from both male and female donors will help resolve this question. We find that the distance traveled in OFT negatively correlates with the donor age, indicating that some donor age-related microbiota changes may affect locomotion (Figure 1H). Additionally, increased repetitive behavior was highly correlated with ADOS and GSI scores (Figure 1H). It is possible that GI co-morbidities in the ASD donors and their correlation with some behaviors (Figure 1B, Table S1) may impact outcomes in experimental mice after microbiota transplant. However, we found no differences in mouse weight and intestinal barrier function between oTD and oASD mice (Figure S3A–B, Figure S3C–H). Further, there were no significant differences in a large panel of cytokines and chemokines from either the terminal ileum or the proximal colon (Figure S3I–J), suggesting no local inflammation in the GI tract of oASD mice as a result of “humanization” with ASD microbiota. Thus, microbiota transplantation from human ASD donors into mice can transfer ASD relevant behavioral deficits.

**TD and ASD Colonized Mice Harbor Different Bacterial Species that Correlate with Behaviors**

To validate the fidelity of microbiota transplantation, we collected feces from mice colonized with human samples (recipient TD and ASD, annotated rTD and rASD), and...
colon contents of their oTD and oASD offspring. As expected, the recipient microbiomes shifted away from that of donors, as seen three weeks after transplantation into mice (Figures S1C–E). We observe a decrease in α-diversity upon colonization of mice (donor to recipients), indicating loss of bacterial species due to sample processing and/or host-incompatibility (Figure S1D). Moreover, specific taxa, such as Actinobacteria and some Firmicutes, failed to engraft in mice, while others such as some Bacteroidetes thrived (Figure S1F–G). Sixty percent of the taxa in donor samples engrafted on average in recipient mice with no differences in engraftment or bacterial loads between oTD and oASD mice (Figure S1H–I, S1J–L). We observed a slight shift in α- and β-diversity in offspring compared to recipients (Figures S1C–E). While oASD mice did not exhibit the same decrease in α-diversity as the human donors (Figure 1I), we did observe a clear separation between oTD and oASD, similar to that in the human donor population, except for recipients of a single ASD-donor (oASD-1) (Figure 1J). oASD offspring displayed different bacterial profiles from oTD controls, driven by various taxa such as Bacteroidetes, β-Proteobacteria, Lactobacillales, Clostridiaceae, and Enterobacteriaceae (Figure 1K). Collectively, fecal transplantation from human donors into GF recipient mice maintained differences between TD and ASD microbiome profiles, which are vertically transmitted to offspring with fidelity.

We identified differentiating bacterial taxa between oTD and oASD microbiota using DESeq2 analysis. In total, 31 amplicon sequence variants (ASVs) were differentially abundant between groups (Figures 2A–2B). Those ASVs belong predominantly to the Clostridia and Bacteroidia classes, with single representatives from the Verrucomicrobia, α- and β-Proteobacteria phyla. ASVs belonging to Bacteroidia were associated with most TD controls. Specifically, *Bacteroides ovatus* (970ed_Bacteroides ovatus and 054dc_Bacteroides ovatus) and *Parabacteroides merdae* (4ae7e_Parabacteroides) were prevalent in all oTD samples, and absent from most or all oASD samples. Conversely, *Eisenbergiela tayi* (02b40_Lachnospiraceae and 29857_Lachnospiraceae) was prevalent among all oASD mice, and absent from oTD groups (Figure 2B). These observations were further corroborated by an unsupervised RandomForest classification analysis. The trained classifier assigned all offspring samples correctly by group. The model indicates 13 ASVs contributing >1% to discrimination between oTD and oASD samples (Figure 2C), including *E. tayi*, *B. thetaiotaomicron*, and *P. merdae* (Figure 2D). Thus, we found that differences in bacterial community composition between oTD and oASD mice were specific to certain taxa. Similar to human studies, β-diversity of bacterial communities differed between oASD and oTD mice (Liu et al., 2019). Specifically, Bacteroidetes, Bacteroides and Parabacteroides were decreased in oASD mice (De Angelis et al., 2015; Strati et al., 2017; Williams et al., 2011), with an increase in Akkermansia, Sutterella and Lachnospiraceae, as has been reported in humans (Kang et al., 2013; Williams et al., 2011).

We next explored whether specific ASVs positively or negatively co-vary with behavioral outcomes. The abundance of three of the four bacterial ASVs significantly correlated with both repetitive and social behaviors in male mice using Spearman’s rank correlation (Figure 2E). The *Bacteroides* (b20cd_Bacteroides) species and *P. merdae* (4ae7e_Parabacteroides) both correlated with reduced repetitive behavior and increased social behavior. Conversely, *E. tayi* (02b40_Lachnospiraceae) showed the opposite effects, as it correlated with increased repetitive behavior and social interaction deficits (Figure 2E). Accordingly, we validated that
16S rRNA gene ASVs that map to *E. tayi*, but not those that map to *P. merdae*, were more abundant in ASD individuals from large human cohort studies (Figure 2F–G). The association of specific bacterial species with oTD or oASD samples, which are also highly correlated with ASD-relevant behaviors, supports the hypothesis that specific bacteria may contribute to various symptoms of ASD.

**ASD Microbiota Promote Extensive Alternative Splicing of ASD-relevant Genes in the Brain**

Social behavior is mediated by multiple brain regions including the prefrontal cortex (PFC) and the striatum (STR) (Barak and Feng, 2016). Synaptic dysfunction and aberrant developmental trajectories in the STR may result in increased repetitive behaviors (Langen et al., 2014; Rothwell et al., 2014). Large scale analyses, comparing expression in brains of TD and ASD individuals highlight differential expression patterns of various genes and non-coding RNAs (Parikshak et al., 2016; Voineagu et al., 2011). RNA-seq analysis revealed few genes with significant differential expression profiles between oTD and oASD mice at P45 (Figures S4A–C). Three long-noncoding RNAs of unknown function from the PFC, and two additional genes from the combined PFC and STR dataset, displayed differential expression between groups of mice (Figures S4A–C, Figure S4D). One protein coding gene of known function, namely *Daglb*, was down-regulated in ASD-colonized mice. Diacylglycerol Lipase Beta (*Daglb*) is involved in endocannabinoid production and affects axonal growth during development (Bisogno et al., 2003; Powell et al., 2015) (Figure S4D). A gene set enrichment analysis (GSEA) highlighted several KEGG pathways that were significantly different in oASD brains (Figure 3A–B). Pathways involving transcription, translation, and protein quality control and export were upregulated in oASD brains (Figure 3A). A KEGG pathway involving RNA processing by the spliceosome was significantly upregulated in oASD mice (Figure 3A).

Given evidence for spliceosome alterations, we investigated whether oASD brains exhibited differential patterns of alternative splicing (AS), a feature found in human ASD brains (Gandal et al., 2018; Irimia et al., 2014; Parikshak et al., 2016; Parras et al., 2018). rMATS analysis (Shen et al., 2014) identified 560 genes that showed different AS events between oASD and oTD mice in either brain region (PFC: 265 events, STR: 257 events, Full dataset: 243 events): 123 with 3’ or 5’ alternative start sites (A3SS/A5SS) events, 78 with mutually exclusive exon (MXE) events, 381 with skipped exon (SE) events, and eight with retained introns (RI). We examined curated lists of high-confidence ASD risk genes, namely SPARK for Autism and the SFARI Gene dataset (Abrahams et al., 2013) (Figure 3C, Table S2). Fifty two of the 560 AS events occurred within genes associated with autism, with 11 present in both the SPARK gene list *and* SFARI Gene dataset, and 52 present in the SFARI gene list (Figure 3C). Differential splicing events were enriched for genes highly expressed in neurons, and under-enriched for in microglia in oASD mice compared to oTD animals (Figure 3D). Interestingly, we found that this dataset of differentially spliced genes was highly enriched for various ribosome binding protein (RBP) targets, but under-enriched in activity dependent transcripts (Figure 3E), suggesting that the gut microbiome can alter splicing programs at the RBP level.
We detected differential splicing events in several ASD-related genes, predominantly in the STR of oASD mice (Figure 3F). Amongst these is the Fragile X Mental Retardation 1 gene (FMR1), required for normal cognitive development (Iossifov et al., 2012; Parikshak et al., 2013; Sittler et al., 1996). oASD mice show decreased inclusion rates of a skipped exon in FMR1 (Figure 3F). We observed an increased inclusion rate of a mutually exclusive exon (MXE) in Neurexin-2 (Nrxx2), a presynaptic adhesion protein strongly linked to ASD (Dachtler et al., 2014; Südhof, 2008) (Figure 3F). Ank2, necessary for neuronal migration (Kordeli and Bennett, 1991; Willsey et al., 2013), exhibited decreased inclusion of a MXE in the STR of oASD mice, compared to oTD controls (Figure 3F). Other genes that show aberrant splicing in the PFC of mice include the calcium voltage-gated channel subunit Cacna1c, mutations in which cause Timothy syndrome (Splawski et al., 2004); adynsucinate lyase Adsl which is associated with infantile autism (Sivendran et al., 2004); Pogz, associated with ASD and intellectual disability (Stessman et al., 2016); as well as Ube3A, aberrant splicing of which can result in Angelman syndrome (Sartori et al., 2008). These data reveal a major shift in alternative splicing patterns of genes in the brains of oASD mice relative to oTD mice, with an enrichment for ASD-related genes in the differentially spliced subset that mirror findings from human brains.

**Microbiota from TD and ASD-colonized Mice Produce Discrete Metabolite Profiles**

Gene expression, splicing, and neuronal function in the brain can be regulated by small molecule metabolites (Nankova et al., 2014). An altered metabolome has been associated with ASD (Aldred et al., 2003; De Angelis et al., 2013; Evans et al., 2008; Kang et al., 2017a; Naushad et al., 2013; Yap et al., 2010), and many small molecules differing between TD and ASD likely result from microbial metabolism (De Angelis et al., 2015; Krajmalnik-Brown et al., 2015). We performed untargeted metabolomics analyses of colon contents from oTD and oASD mice (Figure 4A–B), and corresponding serum (Figure 4C). Twenty-seven out of 313 detected metabolites were significantly different in the colon contents of oASD mice, compared to oTD mice (Figure 4; Table S3) (Figure 4A–F). There were higher concentrations of amino acids in colon contents of oASD mice, similar to reports studying individuals with ASD (De Angelis et al., 2013). Notably, we found differences in several agonists and antagonists of the inhibitory gamma-aminobutyric acid (GABA) and glycine receptors (Figure 4G–I). Specifically, 5-aminovaleric acid (5AV) was significantly lower in oASD mice (Figure 4G). 5AV is a weak GABA_A receptor agonist (Callery and Geelhaar, 1985), and is significantly lower in individuals with ASD (Ming et al., 2012). Lower levels of another weak GABA_A agonist (and a potent glycine receptor agonist), namely taurine, are found in a subset of individuals with ASD (Adams et al., 2011; Park et al., 2017; Tu et al., 2012). Intriguingly, oASD mice have ~50% less taurine compared to oTD mice (Figures 4H). Together, lower levels of 5AV and taurine suggest that gut microbes may impact inhibitory GABA signaling. Conversely, 3-aminoisobutyric acid (3AIBA), a degradation product of thymine and a weak glycine receptor agonist, was increased in oASD mice (Figure 4I). Additional bioactive molecules elevated in colons of oASD mice are the soy-derived isoflavones, genistein and daidzein (Figures 4J). While 21 serum metabolites were differentially abundant (8 identified) in oASD mice versus oTD mice, only genistein is significantly different in both colon contents and serum (Figure 4C, F, J). Various sexually-dimorphic effects on neurodevelopment and behavior are linked to genistein, daidzein and...
their degradation products (Ponti et al., 2017; Rodriguez-Gomez et al., 2014; Westmark, 2014). Elevated levels of these metabolites suggest reduced dietary nutrient metabolizing bacteria in the oASD microbiota (Matthies et al., 2008, 2009).

We analyzed metagenomic data from colon contents of mice by HUMAnN2 (Franzosa et al., 2018), and coupled these data with MIMOSA (Noecker et al., 2016) – a metabolic model-based framework for inferring the contribution of bacterial species and genes to the production and degradation of metabolites measured by NMR and GC-MS analysis (Figures S5). Interestingly, MIMOSA analysis suggested that amino acids were predominantly degraded/utilized by the microbiota in contrast with other metabolites (by specific Akkermansia, Alistipes and Bacteroides species) (Figure 5A, Figure S5A–B, Figure S5C–D). Specific KEGG pathways differentially present in oTD and oASD gut microbiomes, with various chemical structure transformation maps highly represented in oASD mice (Figure S5E). We further found that the metabolism of various amino acids, and specifically that of proline, taurine, and glutamate and glutamine, were differentially represented in the metagenomes of oASD mice (Figure 5B). These data indicate that the oTD microbiota preferentially metabolizes specific dietary amino-acids.

HUMAnN2 and ShortBRED analyses (Franzosa et al., 2018; Kaminski et al., 2015) of metagenomic data enabled exploring possible pathways for taurine and 5AV metabolism. Taurine can be produced by either deconjugation of tauro-conjugated bile acids, such as taurocholic acid, or by decarboxylation of Lcysteate (Figure 5C). HUMAnN2 analysis identified that both bile-salt hydrolase (K01442) and glutamate decarboxylase (K01580) were present at lower abundance in oASD metagenomes. Glutamate decarboxylase catalyzes the conversion of glutamate to GABA, and can also decarboxylate cysteate to taurine (Kim et al., 2009; Wu, 1982). Interestingly, MIMOSA analysis predicted that taurine concentrations may result from differential synthesis potential by three specific species: Alistipes sp. HGB5, Alistipes finegoldii, and Bacteroides xylanisolvens (Figure S5A). 5AV is likely the product of Stickland fermentation of proline (Huang et al., 2018). However, we found no differences in the abundance of proline reductase (Figure S5F–G). Δ1-pyrrolline-5-carboxylate (P5C) is an intermediate of proline production from trans-4-hydroxyproline (Hyp) by HypD (Huang et al., 2018; Levin et al., 2017), which is subsequently reduced to L-proline by P5C reductase (K00286). Additionally, the oxidation of L-proline by proline dehydrogenase (K13821) produces L-glutamate, with P5C as an intermediate (Liu et al., 2017). Hydroxyproline concentrations varied consistently with K00286 abundance (Figure S5B), and hypD levels were not significantly decreased in oASD samples (Figure 5G). However, we found a significant increase in K13821 (Figure 5H) and a significant decrease in P5C reductase (K00286) abundance (Figure 5I) in oASD mice. These data suggest that, in oTD microbiota, L-proline is produced from Hyp via P5C and subsequently serves as an electron acceptor to produce 5AV (Figure 5F–I). Conversely, in oASD microbiota, the balance shifts towards production of P5C and glutamate, and away from 5AV (Figure 5F–I). Together, empiric data and computational predictions suggest that amino acid metabolism may be a key mechanism by which the gut microbiota modulates behavior.
Administration of Metabolites Depleted in ASD Improve Behaviors in a Mouse Model

Microbial metabolites in the gut can impact neurological outcomes (Wang et al., 2018). We next correlated metabolite profiles to human subject metadata (e.g., age, ADOS score, and GSI score) and behavioral outcomes in male mice. Spearman’s rank correlation suggests specific metabolites that distinguish oASD and oTD mice, including taurine and 5AV, may protect mice from development of ASD-like behaviors (Figure 6A). In addition, we predict that genistein and daidzein (or the absence of their degradation products) contribute to repetitive behavior effects while lysine, 3AIBA, and genistein are predicted to influence locomotion (Figure 6A). Integration of microbiome and metabolome profiles enables the testable hypothesis that protective or pathogenic microbial metabolites may regulate specific behaviors associated with ASD.

The presence of both 5AV and taurine in the mouse colon depends on the microbiota (Figure S6A–B) (Matsumoto et al., 2017). We hypothesized that the decreased levels of taurine and 5AV in colon contents of oASD mice (see Figure 4G–H) could have an effect during gestation as well as adulthood.

We orally administered high concentrations (10mM) of either 5AV or taurine to pregnant C57BL/6J mice, and measured the abundance of these metabolites in colon contents, amniotic fluid, and fetal brains (Figure 6B). While 5AV reached the fetal compartment and the fetal brain (Figure 6B), taurine concentrations did not change with administration suggesting it may act locally in the gut.

To test the behavioral effects of 5AV and taurine, we employed the BTBR T+ tf/J (BTBR) mouse model that displays ASD-related behavioral changes (McFarlane et al., 2008; Meyza and Blanchard, 2017; Moy et al., 2007; Silverman et al., 2010). BTBR mice have known microbiome and GI changes relative to C57BL/6 mice (Coretti et al., 2017; Golubeva et al., 2017; Newell et al., 2016), as well as known metabolic deficits (Golubeva et al., 2017; Klein et al., 2016). We orally administered taurine to BTBR mice from conception through adulthood to capture both prenatal and postnatal neurodevelopmental periods, and compared their behavior to untreated animals. Indeed, taurine significantly reduced repetitive behavior, as measured by marble burying, and increased social duration in the DSI test (Figure 6C–D). Additionally, offspring treated with taurine displayed reduced anxiety, as indicated by increased center duration in the OFT (Figure 6E). 5AV was predicted to increase social behavior, based on correlation (Figure 6A). Administration of 5AV from conception through adulthood reduced repetitive behavior in BTBR mice (Figure 6C), although this outcome was not predicted by correlation. Importantly, we validated the predicted positive effects of 5AV on social behavior (Figure 6D). Exposure of taurine and 5AV to developing BTBR mice during the prenatal and weaning periods is critical, as administration to juvenile mice starting at 4 weeks of age and through adulthood did not rescue behavioral alterations (Figure S6C–E). A similar effect was observed when we administered 5AV from weaning to offspring mice colonized with human microbiota from donor ASD3 (Figure S6F–H). Mice administered 5AV showed increased locomotion, decreased center duration (Figure S6F), and increased sociability (Figure S6H), with no significant difference in repetitive behavior (Figure S6G). These findings support the hypothesis that metabolites of gut bacteria can contribute to the manifestations of ASD-like behaviors in mice.
Some forms of ASD are thought to result from an imbalance between excitation and inhibition (E-I) in synaptic transmission and cortical circuitry (Lee et al., 2017; Nelson and Valakh, 2015; Rubenstein and Merzenich, 2003), although a recent report suggests E-I imbalance is not causative in some mouse models (Antoine et al., 2019). E-I imbalance, and its modulation by various treatments, have been reported in BTBR mice (Burket et al., 2013; Lee et al., 2017; Silverman et al., 2012, 2013). Targeting GABAergic signaling has been suggested to be an avenue for intervention in ASD (Cellot and Cherubini, 2014). To test whether 5AV and taurine affect cortical circuitry and perturb E-I balance in BTBR mice, we recorded from pyramidal neurons in layer 5 (L5) of the medial prefrontal cortex (mPFC) by whole-cell patch clamp in acute slices. Specifically, we investigated whether treatment with taurine or 5AV (from conception to adulthood) affected the intrinsic membrane and synaptic (miniature inhibitory or excitatory postsynaptic currents (mIPSC and mEPSC]) properties of pyramidal neurons. Neither 5AV nor taurine affected the intrinsic membrane properties of neurons or the frequency or amplitude of mEPSCs and mIPSCs, compared to controls (Figure S6I, Figure 6F–G). However, L5 pyramidal neurons from mice treated with 5AV, but not taurine, showed significantly decreased excitability as measured by the number of spikes observed as a result of injection of stepwise increasing currents (Figure 6H). Another process hypothesized to affect GABAergic signaling is the GABA excitatory to inhibitory switch during development, although it is still somewhat controversial (Ben-Ari et al., 2012; Valeeva et al., 2016). Since taurine has previously been shown to inhibit the potassium-chloride cotransporter KCC2 (Inoue et al., 2012), it might affect the excitatory-to-inhibitory switch in response to GABA. Primary cortical neurons from embryonic Sprague Dawley rat brains were cultured with taurine, 5AV, or controls (over 17 days in vitro), and responses to GABA exposure by calcium imaging were measured using a calcium-specific dye (Fluo-4). Compared to controls, cortical neurons treated with taurine exhibited a delayed switch from excitatory to inhibitory response to GABA (Figure S6J), suggesting that taurine might affect the development of neurons and their response to inhibitory neurotransmitters. We propose that the human microbiota can modulate complex behaviors in mice via the production of neuroactive microbial metabolites, with mechanisms that include regulation of E-I balances in the brain.

DISCUSSION

A potential link between the microbiota and ASD was suggested almost two decades ago, emboldened by two foundational observations: first it was reported that oral vancomycin treatment resulted in a short-term benefit in a small group of children with ASD (Sandler et al., 2000), and subsequently, Finegold and colleagues surveyed gut bacteria in children with ASD and noted differences compared to controls (Finegold et al., 2002). Since then numerous studies from diverse cohorts have reported that microbiome profiles of ASD individuals, especially those with co-morbid GI dysfunction, differ from that of TD controls (Coretti et al., 2018; De Angelis et al., 2013; Finegold et al., 2010; Gondalia et al., 2012; Kang et al., 2013, 2017a; Kushak et al., 2016; Liu et al., 2019; Son et al., 2015; Strati et al., 2017; Wang et al., 2019; Williams et al., 2011). The high prevalence of GI dysfunction (Adams et al., 2011; Cháidez et al., 2014; McElhanon et al., 2014), along with evidence of
immune imbalance (Onore et al., 2012), further suggest microbiota involvement in ASD. While these compelling association studies in humans suggest gut bacteria may impact behavioral symptoms, a direct contribution by the microbiota to the pathophysiology and behavioral outcomes of ASD has not been described previously. We report herein that colonization of mice with gut microbiota from human donors with ASD, but not from TD controls, is sufficient to promote behaviors in mice consistent with the core behavioral features of ASD. Notably, phenotypes were more pronounced in male offspring mice; future work will address gender differences in mice that the current experimental design cannot resolve since we exclusively utilized male donors. Our results demonstrate that changes to the human microbiota can promote ASD-like behaviors in wild-type mice, but do not conclude that gut bacteria are entirely causal for symptoms. Factors such as altered host genetics and perinatal events, coupled with an altered microbiota, may together influence the etiology of ASD by compounding risks that enhance symptom severity.

The transcriptional program in ASD brains is distinct from that of TD brains (Gandal et al., 2018; Parikshak et al., 2016; Voineagu et al., 2011). RNAseq analysis of “humanized microbiota” mice showed few transcripts differing in expression levels. However, several disease-related pathways were upregulated. Recent studies have highlighted the importance of aberrant alternative splicing of mRNA in the brains of subjects with an ASD diagnosis (Corominas et al., 2014; Gandal et al., 2018; Irimia et al., 2014; Parikshak et al., 2016; Voineagu et al., 2011). Among upregulated KEGG pathways in oASD mice were genes related to the spliceosome, suggesting that the microbiota contribute to splicing regulation. Analysis of gene splicing revealed extensive differences between oTD and oASD mice, with 11 alternative splicing events in validated high-risk ASD genes. These findings suggest that gut microbes not only regulate gene expression in the mouse brain (Hoban et al., 2016; Neufeld et al., 2011; Stilling et al., 2015), but also affect alternative splicing (Stilling et al., 2018), and can regulate the production of specific isoforms of genes that have been implicated in ASD.

Gut bacteria can affect gene expression and host behavior through various pathways, including the production of neuroactive small molecules (Hsiao et al., 2013). Concentrations of several metabolites in the colon and circulation were regulated by the gut microbiota in a donor-specific manner, and we observed impaired amino acid metabolism. Two examples are taurine, the metabolic product of cysteate or taurocholic acid, and 5AV, the fermentation product of proline—both GABA_A receptor agonists that are increased in the colons of oTD mice. Taurine is essential for brain development (Kilb and Fukuda, 2017; Tochitani, 2017) and can be produced by neurons and astrocytes (Vitvitsky et al., 2011) or transported through the blood-brain-barrier via the Taurine transporter TauT (Benrabh et al., 1995). 5AV acts as an anticonvulsant in mice (Dhaher et al., 2014; Samuels et al., 1983). We hypothesized that taurine and 5AV are neuroactive metabolites produced by the microbiota. Indeed, administration of either taurine or 5AV to BTBR mice from conception attenuated ASD-relevant behavioral alterations, namely stereotypies and social impairments. These GABA_A receptor agonists may act to perturb the E-I balance in the brain, specifically during development. Extensive evidence highlight the importance of the E-I balance in neurodevelopmental disorders (Lee et al., 2017; Nelson and Valakh, 2015; Rubenstein and Merzenich, 2003). Administration of 5AV to BTBR mice decreased the excitability of L5
pyramidal neurons in the mPFC. Consistent with these results, social deficits in the CNTNP2-deficient mouse model of autism could be rescued by modulating the excitability of pyramidal neurons (Selimbeyoglu et al., 2017). Our results indicate that taurine can delay the excitatory-to-inhibitory developmental switch in neurons, at least in vitro, and may also act on brain function via other mechanisms (Bellono et al., 2017; Kaelberer et al., 2018). Together, these discoveries provide experimental evidence that microbial metabolites can mediate communication between the gut and brain in the context of modeling ASD in mice.

Recent advances in DNA sequencing technologies have empowered numerous microbiome profiling studies, revealing changes to microbial community compositions across diets, geographies, and diseases. While hypothesis-generating, translating these correlations into actionable outcomes is challenging in humans. GF animals harboring a human microbiota offer an experimental tool to investigate the function of human gut bacteria in a highly controlled environment. This is critical, as ASD is a heterogeneous condition, displaying a wide spectrum of symptom severity among affected individuals, with diverse inherent predispositions and extensive environmental exposures (Lombardo et al., 2019). While ours is a limited study, with 16 donor samples from a pediatric cohort, the results support a hypothesis that the human gut microbiota contributes to ASD phenotypes. Analysis of fecal samples from additional well-characterized cohorts will enable the identification of subsets of ASD individuals whose symptoms may be microbiota-related from those with disparate etiologies. The high concordance rates observed between monozygotic twins implicate a strong genetic basis for ASD (Tick et al., 2016). However, it is important to consider that both human and microbial genes are vertically heritable across generations. Accordingly, we propose that the etiology of ASD may lie in the human genome, the human microbiota, or both via gene-environment interactions. While the exciting prospect of genome editing remains on the horizon, development of microbiota-based interventions such as probiotics, fecal microbiota transplantation, or metabolites may offer a timely and tractable approach to addressing the lifelong challenges of ASD.

STAR Methods

Contact for Reagent and Resource Sharing

Further information and requests for resources and reagents should be directed to and will be fulfilled by the Contacts, Gil Sharon (gsharon@caltech.edu) and Sarkis K. Mazmanian (sarkis@caltech.edu).

EXPERIMENTAL MODEL AND SUBJECT DETAILS

Human fecal samples—For all animal experiments, Arizona State University (ASU) shared human fecal samples with California Institute of Technology (Caltech) with a Material Transfer Agreement and approval to share deidentified data by the Institutional Review Board (IRB) at ASU (ASU IRB protocol #: 1206007979, Caltech IRB protocol # 15–0569). Human fecal samples were previously collected from typically developing children and children with autism spectrum disorders (ASD) at ASU (Kang et al., 2013, 2017). Briefly, parents collected and froze a single fecal sample from each subject. Frozen fecal samples were shipped overnight to ASD with a cold pack, and stored at −80 °C. All
fecal samples and their metadata including gastrointestinal (GI) and ASD-relevant clinical data were de-identified before being shared with Caltech. DNA samples from Kang et al., 2013, 2017 were resequenced and analyzed as specified below.

**Mouse husbandry**—All animal husbandry and experiments were approved by the Caltech Institutional Animal Care and Use Committee (IACUC protocol #1645). Throughout the study, colonized animals were maintained in autoclaved microisolator cages with autoclaved bedding (Aspen Chip Bedding, Northeastern Products Corp, Warrensburg, NY), water, and chow (Laboratory Autoclavable Rodent Diet 5010, LabDiet; St. Louis, MO, USA). Mice were maintained at an ambient temperature of 71–75 °F, 30%–70% humidity, at a cycle of 13 hours light & 11 hours dark.

**Mouse Colonization**—Germ-free (GF) C57BL/6J weanlings (3–4 weeks of age) from the Mazmanian laboratory colony were colonized with fecal samples from human donors. Human fecal samples were collected by the Krajmalnik-Brown laboratory at the Arizona State University as part of a previous study (Kang et al., 2013, 2017), and stored at −80 °C. Aliquots of 16 donor samples were sent to Caltech and used for colonization into GF mice. To that end, frozen aliquots were thawed in an anaerobic chamber and resuspended in two volumes of reduced sodium bicarbonate solution (final concentration 5 %) (Life Technologies; Carlsbad, CA, USA). Subsequently, samples were vigorously vortexed and spun down. Supernatants were then used to colonize GF mice by a single oral gavage (100 μl/mouse; Instech, PA, USA). Colonized mice (4–6 females and 2–3 males per donor) were then allowed to rest for 3 weeks, and were subsequently mated according to donor. Pregnant dams were single-housed at E15.5–17.5, and offspring were weaned at 3 weeks of age. At weaning, different litters born within up to a week apart were combined and housed in groups of 4–5 male or female mice per cage and used for subsequent analyses. Cages were assigned to either behavior testing or for tissue collection. Behavior testing started at 6 weeks of age, while tissues were collected at P45. In the initial stage of this study, we colonized and subsequently behaviorally tested mice with fecal samples from 13 human male donors. Subsequently, we tested and analyzed a subset of representative samples (two TD and three ASD) along with additional previously untested samples (one TD and two ASD), to ensure there is no bias in sample selection.

**METHOD DETAILS**

**Behavior testing**—All mice were tested using the same battery of behavioral tests, starting at six weeks of age, in the following order: open field testing, marble burying, social behavior, and USV (male-female context). Mice were allowed to rest for at least two nights after cage changing before they were tested, and tests were performed 4–7 days apart to allow mice to rest between tests. Mice were acclimated to the behavior testing room overnight to reduce stress and anxiety. Mice were tested during the light phase of the light cycle; to control for time of day effects, cages of different groups were alternated. During the initial discovery phase, the experimenter was blinded to the donor but not to the group. In the subsequent validation phase, the experimenter was blinded. Each donor sample was tested 1–2 times and the aggregated data is presented.
Open field testing (OFT): OFT was performed in 50 × 50 cm$^2$ white plexiglas arenas, recorded using an overhead camera, and tracked and analyzed using the EthoVision XT 10 software package (Noldus Information Technology; Leesburg, VA, USA). Prior to testing, the arena was disinfected using Rescue disinfectant (Virox technologies), followed by 70% ethanol and finally water. Mice were then introduced to the arena and allowed to explore for 10 min while tracked. The total distance traveled, and the number of entries and time spent in a 30 × 30 cm$^2$ center square, were analyzed by the EthoVision XT 10.0 software (Noldus Information Technology; Leesburg, VA, USA).

Marble burying (MB): MB was performed in a normal cage bottom (Lab Products; Seaford, DE, USA) with floor area of 75 in$^2$ filled with 3–4 cm of fresh, autoclaved wood chip bedding (Aspen chip bedding, Northeastern Products Corp; Warrensburg, NY, USA). Mice were first habituated to the cage for 10 min, and subsequently transferred to a holding cage while the bedding was leveled and 20 glass marbles (4 × 5) were placed on top. Mice were then returned to their own cage and removed after 10 min. The number of buried marbles (50% or more covered) was then recorded and photographed for reference. Bedding was replaced for each mouse, and marbles were soaked in 70% ethanol and dried in bedding in between each test. When the experimenter was not blinded to the treatment or group, the number of buried marbles was scored by a second experimenter blinded to the treatment/group from overhead images taken after the second 10 min session.

Three-chamber sociability test: the 3-chamber sociability test was performed in a 60 × 40 cm$^2$ white plexiglass box divided into three chambers (20 × 40 cm$^2$) by clear plexiglass dividers. Mice were first habituated to the full empty arena for 10 min. Subsequently, mice were confined to the center chamber and a stimulus mouse (sex-matched adult SPF C57BL/6J) was placed in a small cage in one chamber (social chamber) while a small object was placed in a cage on the other chamber (non-social chamber). Mice were then allowed to travel between chambers for 10 min, and the movement of mice was recorded by an overhead camera and tracked using the EthoVision XT 10 software package (Noldus Information Technology; Leesburg, VA, USA). A sociability index was calculated by the following: $SI = \frac{\text{time in social chamber}}{\text{(time in social chamber) - (time in nonsocial chamber)}} \times 50 - 100$. Prior to each test, arenas were disinfected using Rescue (formerly Accel) disinfectant (Virox Technologies; Oakville, ON, Canada), followed by 70% ethanol and finally water.

Direct social interaction (DSI) test: As a more sensitive measure for sociability, we also used the direct social interaction test where a mouse is allowed to interact with a stimulus mouse while the interaction is recorded using an overhead video camera. Each mouse was introduced to a fresh empty cage and allowed to habituate for 10 min; grooming behavior was scored for the last five min of this period. Subsequently, a stimulus mouse (either juvenile or adult SPF C57BL/6J or BTBR), depending on the experiment) was introduced to the cage for 6 additional min. A blindered experimenter scored videos for any social approach, aggression, or grooming behavior using the ETHOM software (Shih and Mok, 2000). A set of reference videos was used to ensure consistency over time.
**Ultrasonic vocalization (USV)**:: The male-female paradigm was used to test deficits in communication in male mice. Mice were single-housed and exposed to a new SPF C57BL/6J (or BTBR) female for 10 min every day in the three days prior to the test. On the fourth day, mice were habituated to an empty cage (no bedding) with a filter soaked with a drop of fresh female urine for 10 min. Subsequently, the filter was removed and a novel female was introduced to the cage. Ultrasonic vocalizations were recorded using Avisoft UltraSoundGate 116Hme microphone (Avisoft Bioacoustics) and the Avisoft Sas lab Recorder software (Avisoft Bioacoustics). Total vocalization and vocalization counts were recorded during 3 minute sessions of male-female interaction.

**Tissue Collection**—On P45, offspring mice were sacrificed by first administering 5% isoflurane by inhalation for 30 sec followed by cervical dislocation. Subsequently, blood was collected by heart puncture into 1.1ml z-gel serum collection tubes (Sarstedt; Germany). Serum was then collected according to the manufacturer’s instructions and stored frozen in −80 °C until analysis. Brains were macro-dissected using a mouse brain slicer (1mm coronal section slice intervals; Zivic Instruments; Pittsburgh, PA, USA) and sections of the prefrontal cortex and the striatum were collected into RNALater (Thermo; Waltham, MA, USA) and kept frozen in −80 °C until analysis. Intestines were dissected, colon and cecal contents collected separately and flash frozen while the intestinal tissue (~2 cm of the proximal colon and ~2 cm of the terminal ileum) were rinsed in PBS and frozen in RNALater. To control for effects by the time of collection, mice from different groups were sacrificed in an alternated fashion. All samples were then assigned an identification number that prevented from direct identification of the groups to facilitate blinded analysis of samples downstream.

**Mouse fecal sample collection and microbial DNA extraction**—Frozen mouse fecal samples were shipped overnight on dry ice to ASU and stored in −80 °C until DNA extraction. Human feces that were used as donor samples for the mouse experiments were also shipped back to ASU in order to be processed for microbial DNA extraction and next-generation sequencing together with mouse fecal samples. At ASU, microbial genomic DNA was extracted from fecal samples using the PowerSoil® DNA Isolation Kit (Mobi; Carlsbad, CA, USA) with a modification based on the manufacturer protocol. Quality and quantity of genomic DNA was verified using a NanoDrop ND-1000 spectrophotometer (NanoDrop Technology; Rockland, DE, USA).

**16S rRNA gene sequencing:** Qualified genomic DNA samples were processed for 16S rRNA library preparation and next-generation sequencing at the Microbiome Analysis Laboratory in the Biodesign Swette Center for Environmental Biotechnology (http://krajmalnik.environmentalbiotechnology.org/microbiome-lab.html). The Earth Microbiome Project standard protocols (http://www.earthmicrobiome.org/emp-standard-protocols/) were employed with the barcoded primer set 515F-806R (515F:GTGCCAGCMGCCGCGGTAA, 806R:GGACTACHVGGGTWTCTAAT) that targets the V4 region of the bacterial (and archaeal) 16S rRNA gene (Caporaso et al., 2012). Paired-end, 2×150bp, next-generation sequencing was performed using MiSeq Illumina platform (MiSeq Reagent Kit v2; Illumina Inc.; San Diego, CA, USA) and microbiome sequencing data were analyzed using the
Quantitative Insights Into Microbial Ecology (QIIME2) software package (Bolyen et al., 2018; Caporaso et al., 2010).

**Shotgun sequencing for metagenomics:** A miniaturized version of the Kapa HyperPlus Illumina-compatible library prep kit (Kapa Biosystems; Wilmington, MA, USA) was used for library generation. DNA extracts were normalized to 5 ng total input per sample in an Echo 550 acoustic liquid handling robot (Labcyte Inc; San Jose, CA, USA). A Mosquito HTS liquid-handling robot (TTP Labtech Inc was used for 1/10 scale enzymatic fragmentation, end-repair, and adapter-ligation reactions carried out using). Sequencing adapters were based on the iTru protocol (Glenn et al., 2016), in which short universal adapter stubs are ligated first and then sample-specific barcoded sequences added in a subsequent PCR step. Amplified and barcoded libraries were then quantified by the PicoGreen assay and pooled in approximately equimolar ratios before being sequenced on an Illumina HiSeq 4000 instrument to >30X coverage.

**Microbiome analysis**

**16S rRNA gene:** Demultiplexed sequencing outputs were obtained from the ASU sequencing facility and analyzed using the QIIME 2 (versions 2017.9 and 2018.8) software package according to the suggested workflow (Caporaso et al., 2010; Janssen et al., 2018). Since there was little overlap between forward and reverse reads, only forward reads (~150 bp long) were used for subsequent analysis. On average, 51,729 ± 1,331 reads were obtained per sample (median: 50,134 reads). Low quality bases were first removed from the reads and amplicon sequence variants (ASVs) were obtained using the Deblur denoising plugin (Amir et al., 2017) on reads trimmed to 120 bp present in the 16S reference dataset. Subsequently, fragments were inserted to 16S rRNA gene context by q2-fragment-insertion (Janssen et al., 2018) and alignments were obtained using MAFFT (Yamada et al., 2016) and a phylogenetic tree was generated using FastTree (Price et al., 2009). Alpha and Beta diversities were analyzed using the core-metrics-phylogenetic for observed ASVs, Faith’s phylogenetic diversity, and Pielou’s evenness measures for alpha diversity and unweighted UniFrac and Bray-Curtis for beta diversity measures (Lozupone and Knight, 2005). PCoAs were visualized by EMPoror (Vázquez-Baeza et al., 2013). Taxonomic analysis was performed using the q2-feature-classifier trained on GreenGenes 13_8 99% OTU table (Bokulich et al., 2018; McDonald et al., 2012). Differential abundance analysis was performed using the Phyloseq (1.20.0) and DESeq2 (1.16.1) R packages (Love et al., 2014; McMurdie and Holmes, 2013). Additional differential abundance analyses were performed using LefSe (Segata et al., 2011). To further analyze ASVs that contribute to the discrimination between NT and ASD samples and to behavioral phenotypes, a Random Forest analysis (Liaw et al., 2002), as implemented in QIIME 2, was used.

**Metagenomics:** The metagenomic data was processed using the Oecophylla pipeline (https://github.com/biocore/oecophylla). A total of 10,170,588 ± 996,036 (Mean ± SEM; Median 9,791,965) reads per mouse sample were obtained. The raw reads were examined with FastQC and low quality sequences and unwanted reads (0.044 ± 0.008%, Mean ± SEM; Median 0.03%) were filtered with Bowtie2 (v0.1; Langmead and Salzberg, 2012). The taxonomic composition was profiled using the default parameters of MetaPhlAn2 (Truong et
al., 2015) through the Oecophylla pipeline. The functional gene pathway was profiled using the default settings of HUMAnN2 (Franzosa et al., 2018) through the Oecophylla pipeline with 43.1 ± 1.51% (Mean ± SEM; Median 40.45%) of the reads unassigned. HUMAnN2 uses the UniRef90, MetCyc and MinPath databases along with MetaPhlAn2 and ChocoPhiAn pangenome databases to characterize the pathways and genes in sequences (Truong et al., 2015). Gene family abundance, pathway abundance, and pathway coverage of each sample were generated from HUMAnN2; we used the gene family abundance output biom table for analysis. Differences in relative abundance between the sample groups were calculated with LIMMA (Law et al., 2014) and considered significant if p < 0.05 (Kruskal-Wallis test) after multiple test correction by FDR adjustment.

**RNA Extraction and cDNA synthesis**—Total RNA was extracted from de-identified tubes of mouse tissues using the RNeasy Kit (Qiagen; Germany), according to the manufacturer’s instructions. RNA concentrations and the 260/280 nm absorbance ratio were determined using NanoDrop One (Thermo; Waltham, MA, USA). cDNA was reverse transcribed using iScript cDNA Synthesis Kit (Bio-Rad; Hercules, CA, USA), according to the manufacturer’s protocol using 1 μg total RNA in 20 μL reactions.

**Quantitative Real-Time PCR**—qRT-PCR reactions were carried out in a total reaction volume of 12 l containing: 6 l of 2X Power SYBR Green PCR Master Mix (Applied Bioscience; Foster City, CA, USA), 0.5 l of each 10 M primers, and 5 l cDNA (10 ng per reaction). qRT-PCR were performed in duplicates using 384-well plate format in the ABI PRISM 7900 HT (Thermo; Waltham, MA, USA) with the following conditions: 2 min at 50°C and 10 min at 95 °C, followed by 40 cycles of 15 sec at 95 °C and 1 min at 60 °C, dissociation stage consisted of 15 sec at 95 °C, 15 sec at 60 °C, 15 sec at 95 °C. The house-keeping gene β-actin was used to normalize expression levels between samples, and no template controls (NTCs) were used as negative controls. The following primers were used:

- **ZO1:** Forward: 5'- AGGACACCAAAGCATGTGAG-3', Reverse: 5'- GGCATTCCTGCTGGTTACA-3';
- **Ocldn:** Forward: 5'- TTGAAAGTCCACCTCCTTACAGA-3', Reverse: 5'- CCGGATAAAAAGAGTACGCTGG-3';
- **ZO2:** Forward: 5'- ATGGGAGCAGTACACCGTGA-3', Reverse: 5'- TGACCACCCTGTCATTTTCTTG-3';
- **bActin:** Forward: 5'- GGCTGTATTCCCCTCCATCG-3', Reverse: 5'- CCAGTTGGTAACAATGCCATGT-3'

**Intestinal permeability assay**—10–11 week old offspring “humanized” mice were fasted (water ad libitum) for 4 hours. Subsequently, mice were gavaged with 4 KDa FITC-dextran (100 mg/ml; Sigma; St. Louis, MO, USA) at 600 mg/kg body weight. Four hours after gavage, mice were sacrificed by asphyxiation with CO₂ and blood was collected by cardiac puncture into 1.1ml z-gel serum collection tubes (Sarstedt; Germany) and stored on ice in the dark at 4°C until collection according to the manufacturer’s instructions. 25 L of serum samples were loaded in each well and diluted with an equal volume of 1X PBS. FITC-dextran concentrations were determined by spectrophotofluorometry using Cytation5 (Biotek; Winooski, VT, USA) using wavelength setting of: excitation (485/20), emission
(528/20) against a calibration curve of known FITC-dextran concentrations. Throughout the procedure, the experimenter was blinded to mouse groups.

**Viable and total bacterial counts in feces**—Fecal samples were collected from offspring “humanized” mice and homogenized in 10 μL/mg sterile 1X PBS. Suspensions were serially diluted and plated on Tryptic-Soy Agar plates with 5% sheep blood (TSA; Teknova; Hollister, CA, USA) and Brucella Agar with 5% Sheep blood plates (Teknova; Hollister, CA, USA). Subsequently, plates were incubated aerobically (TSA plates) or anaerobically (Brucella plates) at 37 °C for 48–72 hours. For total 16S rRNA gene quantification, DNA was extracted from 200 l of fecal suspensions using Quick-DNA Fecal/Soil Microbe Miniprep Kit (Zymo; Irvine, CA, USA), following manufacturer’s protocol. Fecal DNA from samples were eluted in 100 μL EB buffer, and concentrations were quantified using NanoDrop One (Thermo; Waltham, MA, USA). Femto Bacterial DNA Quantification Kit (Zymo; Irvine, CA, USA) was subsequently used for absolute quantification of 16S copies in fecal samples, according to the manufacturer’s instructions. qPCR reactions were prepared in duplicates in 96-well plate format and performed on an Eppendorf RealPlex4 (Eppendorf; Germany) with the following conditions: 10 mins at 95 °C, followed by 40 cycles of 30 sec at 95 °C, 30 sec at 50 °C and 1 min at 72 °C, then final extension of 7 mins at 72 °C. 16S concentrations were determined using a calibration curve of known concentrations of *E. coli*.

**Multiplexed determination of cytokines and chemokines in the terminal ileum and proximal colon**—Tissues were collected (terminal ileum and proximal colon) from “humanized” offspring mice and stored at −80 °C until extraction and analysis. Total protein was extracted using the Thermo Tissue extraction buffer I (Thermo; Waltham, MA, USA) by bead-beating with ceramic beads (Lysing Matrix D; MP Biomedicals; Santa Ana, CA, USA) at 3,000 rpm for 2 × 30 sec, lysates were then centrifuged 3 min at 16,000 × g at 4 °C and supernatants were collected. Protein concentration in lysates was determined by Pierce-BCA Protein Assay Kit (Thermo; Waltham, MA, USA), according to the manufacturer’s instructions and lysates were adjusted to 200 μg/ml with extraction buffer. 50 l lysate were diluted 2X in sample dilution buffer and analyzed in duplicates by multiplex ELISA using a mouse cytokine 23-plex (Bio-Plex Pro Mouse Cytokine 23-plex Assay) and Bio-Plex® 200 Systems (BioRad; Hercules, CA, USA) according to the manufacturer’s instructions. Analytes were quantified in each sample against a calibration curve of known concentrations.

**Brain gene expression analysis**—Brain tissue from prefrontal cortex and striatum was macro-dissected and flash frozen on dry ice. Approximately 30 mg of frozen brain tissue was then pulverized and RNA was extracted using Qiagen miRNAeasy kits according to the manufacturer’s instructions. RNA sequencing libraries were prepared using TruSeq Stranded mRNA Library Prep kits using polyA selection (Illumina; San Diego, CA, USA), and subsequently sequenced twice on an Illumina HiSeq 4000 with standard chemistry and protocols for 69 base pair paired end reads (UCLA Neuroscience Genomics Core), to achieve an average depth of 56 million reads per sample. Demultiplexed fastq files were mapped to the mouse reference genome assembly (GRCm38/mm10) using STAR with
Gencode M10 annotations. Quality control was performed using PicardTools to generate a matrix of sequencing-related metrics for each sample (CollectAlignmentSummaryMetrics, CollectRnaSeqMetrics, CollectGcBiasMetrics, CollectInsertSizeMetrics, MarkDuplicates). Two sequencing statistics, seqPC1 and seqPC2, were calculated as the first and second principal components of this matrix and were used as covariates in downstream analyses as previously published (Parikshak et al., 2016). Gene expression was quantified using featureCounts. Genes were filtered to retain only those (n=15695) with a minimum of 10 counts in at least half of the samples. Outlier samples (n=3) were identified and removed. Count-level data then underwent TMM scale normalization, followed by voom transformation and differential gene expression (DGE) using the limma package (Law et al., 2014) in R using the following covariates: Group, Brain Region, RIN, seqPC1, and seqPC2. The limma:~duplicateCorrelation function was used to account for non-independence of mice exposed to the same microbiome donor. Test statistics were calculated for the group comparison and local FDR correction was applied to account for multiple comparisons using the fdrtool package in R (Strimmer, 2008). Genes with FDR < 0.1 were identified as being differentially expressed. Gene-set enrichment analysis (GSEA; Subramanian, et al., 2007) was performed on genes ranked by their differential expression T-statistic using the clusterProfiler (Yu et al, 2012) package in R with GO, KEGG, and hallmark gene sets downloaded from http://software.broadinstitute.org/gsea/msigdb/genesets.jsp.

Analysis of event-level differential splicing was performed using rMATS (v3.2.5; Shen et al., 2014). BAM files from ASD and NT groups were first merged. Percent spliced in (PSI) values were calculated for several classes of alternative splicing events, including skipped exon (SE), alternative 5’ splice site (A5SS), alternative 3’ splice site (A3SS), mutually exclusive exons (MXE), and retained introns (RI). Events with FDR < 0.1 were considered differentially spliced across groups. Enrichment of known autism risk genes (SFARI: https://gene.sfari.org/, SPARK for Autism: http://spark-sf.s3.amazonaws.com/SPARK_gene_list.pdf) among those exhibiting DS was assessed using logistic regression, controlling for gene length.

Cell-type specific expression analysis of differentially spliced genes was performed using the pSI package (specificity index; http://genetics.wustl.edu/jdlab/psi_package/) in R (Dougherty et al., 2010; Xu et al., 2014). Cell-type specific gene expression data was obtained from an RNAseq study of purified populations of neurons, astrocytes, oligodendrocytes, microglia, and endothelial cells derived from mouse cortex (Zhang et al., 2014). Significance was assessed using Fisher’s exact test with a pSI threshold set to 0.05, followed by Bonferroni correction of p-values.

Finally, we assessed whether differentially expressed genes were enriched for known targets of several ribosomal-binding protein (RBP) splicing factors. We manually curated lists of splicing targets derived experimentally using CLIP-seq and/or RBP knockout experiments in mice for the following RBP families: MBNL (Weyn-Vanhentenryck et al., 2018), RBFOX (Lee et al., 2016; Weyn-Vanhentenryck et al., 2018), PTBP (Vuong et al., 2016; Weyn-Vanhentenryck et al., 2018), NOVA (Weyn-Vanhentenryck et al., 2018; Zhang et al., 2010), SRRM4 (Raj et al., 2014). Fisher’s exact test was used to calculate enrichment with background set to those genes exhibiting any alternative splicing in our dataset.
Metabolomics analysis—De-identified colon contents and serum samples were collected and flash-frozen at P45 without any buffers, and were shipped to the Dept. of Energy Pacific Northwest National Laboratory for metabolomic analysis by NMR and GC-MS. In colon contents, a total of 122 metabolites were identified by GC-MS (out of a total of 246 detected), and 67 metabolites were detected and identified by NMR. In serum, a total of 130 metabolites were identified by GC-MS (out of a total of 255 detected).

GC-MS sample preparation and analysis: Metabolites were extracted from murine colon contents and plasma samples using methanol (Deroussent et al., 2011; Snijders et al., 2016). Feces were homogenized and weighed, and chilled methanol (−20 °C) was added proportionally to the colon content sample (1 mL to 100 mg). Glass beads were added and the suspension was agitated and sonicated to extract metabolites. Supernatant was collected after centrifugation (15,000 g × 5 min at 4 °C) and 100 μL of each methanol layer was transferred to a new clean vial and subsequently dried under a speed-vacuum concentrator. 50 μL of serum samples were thawed and 200 μL of chilled methanol was added to denature proteins. Supernatants were collected after centrifugation (15,000 g × 5 min at 4 °C). All the samples were then dried completely and stored at −70 °C freezer until the instrumental analysis. Prior to analysis, the stored extracts were completely dried under speed-vacuum to remove moisture and were subsequently derivatized chemically, by methoxyamination and trimethylsilylation (TMS), as reported previously (Snijders et al., 2016). Briefly, methoxyamine (20 μL of a 30 mg mL−1 stock in pyridine) was added to each sample, followed by incubation at 37 °C with shaking for 90 min. subsequently, N-methyl-N(trimethylsilyl)trifluoroacetamide (MSTFA) with 1% trimethylchlorosilane (TMCS) (80 μL) was added to each vial, and incubated at 37 °C with shaking for 30 min. Samples were then allowed to cool to room temperature and were analyzed on the same day. Metabolites were resolved by gas chromatography using a HP-5MS column (30 min × 0.25 mm × 0.25 μm; Agilent Technologies). Samples (1 μL) were injected in splitless mode, and the helium gas flow rate was determined by the Agilent Retention Time Locking function based on analysis of deuterated myristic acid (Agilent Technologies; Santa Clara, CA, USA). The injection port temperature was held at 250 °C throughout the analysis. The GC oven was held at 60 °C for 1 min after injection, and the temperature was then increased to 325 °C by 10 °C/min, followed by a 10 min hold at 325 °C. The transfer line between GC and MS was maintained at 280 °C. All the MS data were collected over the mass range of 50–550 m/z under standard electron impact (EI) ionization mode at 70 eV of ionization energy. GC-MS raw data files were processed using the Metabolite Detector software (v2.5 beta; Hiller et al., 2009). Retention indices (RI) of detected metabolites were calculated based on the analysis of the FAMEs mixture (C8–C28), followed by their chromatographic alignment across all analyses after deconvolution. Metabolites were initially identified by matching experimental spectra to a PNNL augmented version of Agilent GC-MS metabolomics Library, containing spectra and validated retention indices for over 850 metabolites. Subsequently, any unknown peaks were matched to the NIST14 GC-MS library. All metabolite identification and quantification ions were validated and confirmed to reduce deconvolution errors during automated dataprocessing and to eliminate false identifications.
**Proton NMR Metabolomics:** A global metabolomics approach was used to obtain assignment and quantitation of metabolites via nuclear magnetic resonance ($^1$H NMR). The one-dimensional (1D) $^1$H NMR spectra of all samples were collected in accordance with standard Chenomx (Edmonton, Alberta, Canada) sample preparation and data collection guidelines (Weijie, 2006). Fecal extract samples were diluted by 10 % (v/v) spike of a National Institute of Standards and Technology calibrated reference solution (100 % D$_2$O, 5 mM 2,2 dimethyl-2-silapentane-5-sulfonate-d$_6$ (DSS), and 0.1 % sodium azide). All NMR spectra were collected using a Varian Direct Drive 600 MHz NMR spectrometer equipped with a 5 mm triple-resonance salt-tolerant cold probe. The 1D $^1$H spectra were collected following standard Chenomx data collection guidelines (Weljie et al., 2006), employing a 1D NOESY presaturation (TNNOESY) experiment with 65536 complex points and at least 512 scans at 298 K. A presaturation delay of 1.5 sec was used to optimize water suppression. The 1D $^1$H NMR spectra of all samples were processed, assigned, and analyzed by using Chenomx NMR Suite 8.1 (Chenomx Inc.; Edmonton, AB, Canada) with quantification based on spectral intensities relative to the internal standard. Candidate metabolites present in each of the complex mixture were determined by matching the chemical shift, J-coupling, and intensity information of experimental NMR signals against the NMR signals of standard metabolites in the Chenomx library which include metabolites from the HMDB database.

**Metabolomics data analysis:** Data collected by GC-MS and NMR were log2 transformed. Sample outliers were identified and removed based on the RMD-PAV algorithm (Matzke et al., 2011) and a p-value threshold of 0.0001; based on this criterion, three samples were removed. An ANOVA filter (Webb-Robertson et al., 2010) was implemented which removed peaks that have inadequate data to perform a simple ANOVA test for any of the comparisons of interest. Finally, a global median normalization was applied to the data to correct for total metabolite content.

A mixed effects linear model was fit to the data, using the R package lme4 (Bates et al., 2015), with diagnosis (TD, ASD) as a fixed effect and the donor included as a random effect. A maximum likelihood test was conducted to test the null hypothesis that the mean metabolite abundance was equal across treatment groups (Chambers and Hastie, 1992).

**Targeted metabolomics for taurine and 5-aminovaleric acid:** Tissues (colon contents, serum, amniotic fluid, and fetal brain) were collected from age-matched GF and SPF E16.5 C57BL6/J dams or from SPF E18.5 C57BL/6 dams administered 10 mM 5AV, 10 mM taurine, or vehicle in drinking water from E0.5. Throughout the extraction, samples were kept at 4 °C on ice. Colon contents and fetal brains were homogenized in MilliQ water (4 μl / mg) by bead-beating with ceramic beads (Lysing Matrix D; MP Biomedicals; Santa Ana, CA, USA) at 3,000 rpm for 2 × 30 sec. Subsequently, a volume of 0.4 N Perchloric Acid spiked with known amounts of heavy standards (Taurine 1,2-13C2, 98% and Lysine:2HCl 13C6, 99%; 15N2, 99; Cambridge Isotope Laboratories; Tewksbury, MA, USA) in water was added to each volume of both water-soluble tissue extracts, serum, or amniotic fluid, to a final concentration of 0.2 N and samples were vigorously vortexed for 15 sec. Tubes were then centrifuged for 20 min, at 10,000 × g, at 4 °C, supernatants were collected onto an UltraFree MC-GV 0.22 m centrifuge PVDF filter (Millipore; Burlington, MA, USA) and

Cell. Author manuscript; available in PMC 2020 May 30.
centrifuged again for 5 min, at 11,500 × g, at room-temperature. Filtrates were collected and subsequently analyzed by LC-MS/MS.

Analysis of the samples was performed on the ABSciex QTRAP 6500 LC-MS/MS system (Framingham, MA, USA), equipped with an Eksigent ekspert nanoLC 425 pump, ekspert nanoLC400 autosampler and Analyst software. Samples were directly injected (2 min) onto an Intrada amino acid column 1mm × 30mm (Imtakt USA; Portland, OR, USA) kept at room temperature. Chromatographic separation was achieved using a 50 μl/min flow rate and a linear gradient of 0 to 30 % B within 1 min; 30–100 % B in 2 min, followed by 100 % B for 2 min and equilibration for 2 min. Solvent A is 0.3 % formic acid in Acetonitrile and solvent B is 100 mM ammonium formate in 20 % acetonitrile. For all MRM experiments, 6500 QTrap acquisition parameters were as follows: 5500 V Ion-spray voltage, curtain gas setting of 30 and nebulizer gas setting of 20, interface heater at 150° C, 2.5 × 10–5 torr base pressure, and Q1 and Q3 set to unit resolution (0.6–0.8 Da full width at peak half-height). MRM acquisition methods were constructed with metabolite-specific tuned de-clustering potential (DP) and collision energy (CE) voltages. A default collision cell exit potential of 15 V was used for all MRM ion pairs. Raw data were analyzed using Skyline (MacLean et al., 2010) and peak areas were normalized to heavy standards.

MIMOSA integrative analysis—We used a metabolic modeling-based framework, MIMOSA, to identify metabolites whose variation across samples can be explained by variation in the metabolic potential of the microbiome (Noecker et al., 2016). Specifically, we used HUMAnN2 output, regrouped to KEGG pathways. We then analyzed each metabolomics dataset separately using the R package MIMOSA version 1.0.1 (http://elbo.gs.washington.edu/software_MIMOSA.html). MIMOSA constructs a community-wide metabolic model based on the inferred gene content of each sample and calculates community metabolic potential (CMP) scores, representing the relative capacity of the predicted community enzyme content in that sample to synthesize or degrade each metabolite. It then compares variation in these scores across samples to variation in measured metabolite concentrations using a rank-based Mantel test, to identify metabolites for which variation in concentration across samples is positively associated (consistent) with variation in community metabolism (as predicted by the CMP scores), using a local FDR q-value < 0.01. We identified metabolites for which variation in concentration across samples is negatively associated (contrasting) with CMP scores, with the same significance threshold. To identify potential contributing taxa for each metabolite, we calculated the Pearson correlation between the CMP scores obtained for a given metabolite across samples using the entire community and the CMP scores generated based on each species by itself (that is, recalculating the metagenome content and CMP scores based solely on the abundance of this species). OTUs for which this correlation coefficient for a given metabolite was greater than 0.5 were classified as potential contributing OTUs for that metabolite. Potential contributing genes were identified by calculating the Pearson correlation between the vectors of CMP scores obtained with and without reactions linked to that gene. Metabolites for which all main potential contributing genes were exclusively involved in synthesis reactions were classified as “Primarily predicted by synthesis”, and as
“Primarily predicted by degradation” for those whose main potential contributors were exclusively involved in degradation reactions.

**Metabolite administration**—To test the effects specific metabolites have on behavioral phenotypes, metabolites were administered *ad libitum* in drinking water at a final concentration of 10 mM starting either three weeks before mating (pre-pregnancy group), or at 3–4 weeks of age (post-weaning group). Adult offspring (pre-pregnancy group) or adult treated animals were then tested for ASD-relevant behavioral phenotypes. Treatment continued throughout behavioral testing. To test the effects of potentially therapeutic compounds, BTBR *Ipr3tf/J* mice were treated and tested. Throughout these experiments, mice were housed under standard conditions, with autoclaved water and irradiated chow *ad libitum* (PicoLab Rodent Diet 20 5053, LabDiet; St. Louis, MO, USA).

**Slice Electrophysiology**—Adult BTBR mice (8–12 weeks old) were first deeply anesthetized by intraperitoneal injection of ketamine/xylazine and then perfused transcardially with ice-cold sucrose slicing solution (sucrose 213 mM, KCl 2.5 mM, NaH2PO4 1.2 mM, NaHCO3 25 mM, glucose 10 mM, MgSO4 7 mM, CaCl2 1 mM, pH 7.35). After decapitation, brain was removed and immersed in the same ice-cold slicing solution. Coronal slices (300 μm) of medial prefrontal cortex were cut using a vibratome (VT-1200s; Leica; Buffalo Grove, IL, USA). We first let the slices recover in artificial cerebrospinal fluid (ACSF; 124 mM NaCl, 2.5 mM KCl, 1.2 mM NaH2PO4, 24 mM NaHCO3, 25 mM glucose, 1 mM MgSO4, 2 mM CaCl2) at 33 °C for 30 min and then held them at room temperature (~22 °C) until use.

During recording, slices were perfused continuously (~2 mL/min) with ACSF at 25 °C. Neurons were visualized and targeted using an upright IR-DIC microscope (BX51WI; Olympus; Center Valley, PA, USA). Whole-cell recordings were achieved using glass pipettes with an impedance of 3 to 6 MΩ when filled with intracellular solution (for current clamp, 145 mM K-glucanate, 2 mM NaCl, 4 mM KCl, 10 mM HEPES, 0.2 mM EGTA, 4 mM Mg-ATP, 0.3 mM Na-GTP, pH 7.25; for miniature IPSC, 145 mM CsCl, 2 mM MgCl2, 10 mM HEPES, 0.2 mM EGTA, 5 mM QX-314-Br, 2 mM Na2ATP, Na-GTP 0.3 mM, pH 7.25; for miniature EPSC, 145 mM Cs(CH3)SO3, 2 mM MgCl2, 10 mM HEPES, 0.2 mM EGTA, 5mM QX-314-Br, 2 mM Na2ATP, 0.3 mM Na-GTP, pH 7.25). Electrical signal was sampled at 20 kHz and filtered at 2.9 kHz using an EPC 10 system (HEKA Elektronik; Holliston, MA, USA). Liquid junction potential was not corrected. To isolate the miniature EPSC/IPSC, we include synaptic blockers in ACSF (for mEPSC, 0.5 μM TTX, 100 μM picrotoxin; for mIPSC, 0.5 μM TTX, 10 μM CNQX, 25 μM DL-APV). Membrane potential of pyramidal neurons was held at −70/−60 mV.

**Calcium imaging**—Primary E18.5 Sprague Dawley rat cortical neurons (BrainBits; Springfield, IL, USA) were dissociated in papain (2 mg/ml; BrainBits, Springfield, IL, USA), according to the manufacturer’s instructions. Dissociated cells were resuspended in Neurobasal media (Gibco; Waltham, MA, USA) supplemented with 2 % B27-Plus (Gibco, Waltham, MA, USA), 1 % Glutagro (Corning; Corning, NY USA), and 1 % penicillin and streptomycin (Corning; Corning, NY USA). Cells were plated on Poly-D-Lysine pre-coated glass coverslips (Neuvitro; Vancouver, WA, USA) at 60,000 cells / cm2. Cells were
incubated in a humidified incubator at 37 °C and 5 % CO₂ for 6–17 days, and half of the media volume in each well was changed every 3 days. Before imaging, cells were loaded with Fluo-4-AM for 15 min at 37 °C. Fluo-4-AM was prepared in HEPES-buffered solution (HBS) containing: 150 mM NaCl, 3 mM KCl, 3 mM CaCl₂, 2 mM MgCl₂, 10 mM HEPES, 5 mM glucose, pH 4. During imaging, cells were perfused continuously with HBS at 25 °C. CNQX (10 μM) was added to the bath to block glutamatergic excitation. GABA (100 μM in HBS) was puff applied through a glass pipette (~1 μm tip diameter), placed 10–300 μm away from imaged cells, and air pulses (4–6 psi, 50ms) were generated by a Picospritzer system (Parker Hannifin; Cleveland, OH, USA). Illumination was provided by a halogen lamp and images were taken every 1 sec using a Rolera-XR camera (QImaging; Surrey, BC, Canada) controlled by Micro-Manager software (exposure duration 50 ms).

Data analysis was carried out using Matlab software. To quantify the calcium elevation triggered by GABA, we calculated F/F₀ of each cell and a F/F₀ higher than 5 % was considered a positive response. The final GABA switch curve was the best fitting to a logistic function: \( y = \frac{1}{1 + e^{bx}} \).

### QUANTIFICATION AND STATISTICAL ANALYSIS

Statistical analysis for behavioral outcomes in fecal transplanted offspring. Comparison of behavioral outcomes between TD Controls and ASD donors were tested using longitudinal linear mixed effects analyses, with test cycles and donors treated as repeated factors. Analyses were performed in SPSS (v 24); a priori alpha = 0.05. All outcomes were tested for normality and transformed as required. Diagonal covariance matrices were used so that intra-cycle and intra-donor correlations were accounted for in the modeling. The donor type (TD vs ASD) was the primary fixed effect measured, and mouse sex was an a priori covariate. Raw outputs from these analyses are included as supplementary data. Additional statistical analysis was done using R (3.4.1) or Python (3.6.4), using various packages to test mixed effects testing diagnosis (TD or ASD) as a fixed effect and donor and testing round as random effects. Wilcoxon and robust statistics to test 1-way ANOVA and t-tests on trimmed means, based on a generalization of the Welch method (t1dway, lincon, yuen, t=0.1; WRS2 0.9–2 (Mair, Wilcox, and Schoenbrodt 2017). Spearman’s rank correlations were performed using donor metadata and mouse behavior data (average behavior for all males in each donor group). Benjamini-Hochberg correction was performed for multiple comparison corrections. p-values ≤0.05 were considered significantly different. Visualization and additional statistical analysis was performed using Python (3.6.3), using the Matplotlib (2.2.3), Seaborn (0.7.1), StatsModels (0.9.0), Scipy (0.19.1), Pandas (0.23.4), pymer4 (0.6.0; Jolly, 2018), rpy2 (2.9.5) and Numpy (1.13.3) packages.

Test statistics and p-values for data presented in all figures is included in Table S4.

### DATA AND SOFTWARE AVAILABILITY

Raw and analyzed data used to produce all figures are available at the following links:

Mendeley Data [http://dx.doi.org/10.17632/ngzmj4zkms](http://dx.doi.org/10.17632/ngzmj4zkms) Human donor microbiome raw data are available in SRA (16S: PRJNA533120).
Mouse recipient microbiome raw data are available in SRA and EBI (16S: PRJNA431279, Shotgun: ERP113632 or Qiita (Gonzalez et al., 2018) study ID 11809).

RNA-seq raw data The data discussed in this publication have been deposited in NCBI’s Gene Expression Omnibus (Edgar et al., 2002) and are accessible through GEO Series accession number GSE109827 (https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE109827).

Metabolomics raw data Metabolights MTBLS726

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

ACKNOWLEDGMENTS

The authors would like to thank Drs. H. Chu, G. Lenz, C. Schretter, and D. Dar, and members of the Mazmanian laboratory for critical discussions. We thank the staff at the Caltech Office of Laboratory Animal Resources. We also thank Y. Huang for hypD reference sequences. We thank Dr. J. Adams for critical review on the manuscript. We also thank Dr. J. Maldonado and M. Bennett for their support on 16S rRNA gene sequencing. We thank G. Humphrey, J. DeRight Goldasich, T. Schwartz, R. Salido Benitez, and G. Ackermann for their support in shotgun sequencing. Metabolomics analyses were supported by the Microbiomes in Transition (MinT) Initiative as part of the Laboratory Directed Research and Development Program at PNNL. Metabolomics measurements were performed in the Environmental Molecular Sciences Laboratory, a national scientific user facility sponsored by the U.S. Department of Energy Office of Biological and Environmental Research and located at PNNL in Richland Washington. PNNL is a multi-program national laboratory operated by Battelle for the DOE under contract DE-AC05-76RL0 1303. This work was supported by Autism Speaks Postdoctoral Fellowship in Translational Research 9718 and Human Frontiers Science Program Long-Term Fellowship 201265 (to G.S.), SFARI Bridge to Independence Award (to M.I.G), The San Diego Diversity Fellowship and the National Biomedical Computation Resource (to B.C.T). Funding includes grants from NIH (GM124312-01 to E.B., NS104925 to C.L., HD055784, MH100027 to D.H.G, and MH100556 to S.K.M.), Autism Research Institute, the Emch Foundation, the Brenen Hornstein Autism Research & Education Foundation (to D.W.K. and R.K.B.), Lynda and Blaine Fetter, the Simons Foundation, and the Heritage Medical Research Institute (to S.K.M.).

REFERENCES


Cell. Author manuscript; available in PMC 2020 May 30.


Cell. Author manuscript; available in PMC 2020 May 30.


HIGHLIGHTS

- Mice harboring human ASD, but not TD, microbiomes exhibit ASD-like behaviors
- ASD and TD microbiota produce differential metabolome profiles in mice
- Extensive alternative splicing of risk genes in brains of mice with ASD microbiota
- BTBR mice treated with 5AV or taurine improved repetitive and social behaviors
Figure 1. Colonization of mice with ASD microbiomes reproduces human behaviors.

(A) Experimental design: germ-free mice were colonized with fecal samples from TD or ASD donors at weaning and bred at 7–8 weeks of age. Offspring were behaviorally tested starting at 6 weeks of age, and various tissues and samples were collected at P45.

(B) Donor metadata. Metadata for sixteen donors used for mouse colonization, of which eight were followed up on with downstream analysis (in bold). See Table S1.

(C) $\alpha$-diversity in human TD (circles) and ASD (mild ASD-blue squares, ASD-red squares) donors as measured by observed amplicon sequence variants (ASVs) from 16S rRNA gene sequencing of human TD and ASD donors. Eight samples used downstream are in dark-grey. Differences in medians tested by Kruskal-Wallis.

(D) First two axes of a principal coordinate analysis (PCoA) of unweighted UniFrac distances from 16S rRNA gene sequencing of human TD and ASD donors. $N_{TD}=5$, $N_{ASD}=8$. Darker symbols denote samples in bold in Figure 1B. Group differences were tested by pairwise PERMANOVA.

(E-G) Behavioral phenotypes in humanized mice: (E) Number of marbles buried in Marble burying (MB) test (Cohen’s $d_{oTD-oASD}=0.64$), (F) time socializing in direct social
interaction (DSI)(Cohen’s $d^{\text{TD,oASD}} = -0.45$), and (G) distance traveled in open field testing (OFT)(Cohen’s $d^{\text{TD-oASD}} = -0.58$); in colonized offspring colored by donor. Hypothesis testing for differences of the means were done by a mixed effects analysis using donor diagnosis and mouse sex as fixed effects and donor ID as a random effect. p-values were derived from a chi-square test. $N_{oASD}= 121$, $N_{oTD}= 85$ (8–23 mice per donor, per gender). Data presented is the aggregate of all experiments.

(H) Spearman’s rank correlation between mouse behavior and donor metadata (see Table S1). Benjamini-Hochberg adjusted p-values for significant ($\alpha \leq 0.05$) correlations are noted. Color scale denotes Spearman’s $\rho$ from purple (positive correlation) to green (negative correlation). GSI: Gastrointestinal Severity Index; StdADOS: standardized Autism Diagnostic Observation Schedule score; PDDBI: Pervasive Developmental Disorder Behavior Inventory.

(I) $\alpha$-diversity in humanized oTD and oASD mice as measured by observed amplicon sequence variants (ASVs) from 16S rRNA gene sequencing of human TD and ASD donors. Differences in medians tested by Kruskal-Wallis. Data are colored by donor. N=4–7 male offspring per donor.

(J) First three axes of a PCoA of unweighted UniFrac distances from oTD (circles) and oASD (squares) male offspring mice (colored by donor) from 16S rRNA gene sequencing of human TD and ASD donors. Group differences were tested by pairwise PERMANOVA. N=4–7 male offspring per donor.

(K) GraPhLan plot of LefSe linear discriminant analysis of microbiome profiles up to the genus level from 16S rRNA gene sequencing of human TD and ASD donors. Highlights denote significant taxonomic differences between oTD and oASD mice. N=4–7 male offspring per donor.

See also Figures S1–S3, Table S1.
Figure 2. Lachnospiraceae, Bacteroides, and Parabacteroides are differentially abundant in the oTD and oASD microbiomes.

(A) Volcano plot of differential bacterial abundance analysis as calculated by DESeq2 from 16S rRNA gene sequencing. Fold change as a factor Benjamini-Hochberg corrected p-values are plotted for each taxon. Significantly different taxa ($\alpha \leq 0.001$) are colored according to their phylum.

(B) Heat map of differentially abundant amplicon sequence variants (ASVs) by DESeq2 ($\alpha \leq 0.001$) from 16S rRNA gene sequencing. Features are named by their taxonomy with a unique feature identifier. Samples are clustered by Bray-Curtis distances.

(C) Microbiome features (ASVs) contributing >1% to classification between oTD and oASD samples by Random Forest. Taxon abundances from offspring mice were used to train a supervised Random Forest classifier based on donor diagnosis (oTD/oASD; accuracy ratio over baseline: 1.75). Taxa are ordered by their contribution to correct classification of microbiomes by diagnosis.
(D) Relative abundance of select taxa in the microbiome of male offspring, colored by donor. Hypothesis testing for differences of the means were tested by a linear mixed effects analysis with diagnosis as a fixed effect and donor ID as a random effect. N_{TD}=15, N_{ASD}=20 (4–7 mice per donor).

(E) Abundance of select taxa in the offspring microbiome is correlated with behavior of male offspring. Spearman’s rank correlation between the microbiome and mouse behavior, by donor (as in Figure 1). Benjamini-Hochberg adjusted p-values (α ≤0.05) for significant correlations are noted. Color scale denotes Spearman’s ρ from purple (positive correlation) to green (negative correlation).

(F-G) Relative abundance of P. merdae and E. tayi in the original human cohorts. Hypothesis testing by one-tailed Mann-Whitney U test. N_{TD}=32, N_{ASD}=42.
Figure 3. The microbiome impacts gene expression and alternative splicing of high confidence ASD genes in the mouse brain.

(A–B) KEGG pathways upregulated (A) and downregulated (B) in the brains of oASD mice by Gene Set Enrichment Analysis (GSEA).

(C) Venn diagram of differentially spliced genes in the STA and/or PFC between oTD and oASD mice (ASD microbiome Spliced Genes; FDR ≤0.05), and their overlap with known ASD genes as curated by SPARK (odds ratio: 4.12 (95% CI 2.16–7.88), p < 0.0001) and SFARI Gene dataset (4 syndromic genes, 21 genes categories 1–3, and 13 genes category 4 and above; odds ratio: 1.39 (95% CI 1.01–1.92), p = 0.0401). Differential splicing events were identified by rMATS.

(D) Cell-type enrichment analysis of differentially-splicing events in brains of oASD mice. Odds ratio and 95% confidence intervals are presented.

(E) Enrichment of differentially-spliced events amongst previously reported targets of specific RNA-binding proteins and activity-dependent events in the brain.
(F) Examples of differential splicing events (FDR ≤0.05) in genes present in both SPARK and SFARI Gene. Data points colored by donor. PFC: N_{oASD}= 19, N_{oTD}= 14; STR: N_{oASD}= 20, N_{oTD}= 14 (3–6 mouse samples per donor/tissue). Benjamini-Hochberg corrected p-values were calculated by rMATS.
See also Figure S4, and Table S2.
Figure 4. oTD and oASD microbiomes imprint the colonic and serum metabolome of mice.

(A–C) Volcano plots of differentially abundant metabolites identified by an untargeted metabolomics of (A) colon contents by GC-MS, (B) colon contents by $^1$H NMR, and (C) serum by GC-MS. Significantly different metabolites with more than 50% difference are marked in red, and those with modest effects (<50%) are marked in yellow. N_{oASD} = 20, N_{oTD} = 15 (4–7 mice per donor). p-values were calculated using the maximum likelihood test of a mixed effect linear model.

(D–F) Heat maps of differentially abundant metabolites identified by an untargeted metabolomics of (D) colon contents by GC-MS, (E) colon contents by $^1$H NMR, and (F) serum by GC-MS. N_{oASD} = 20, N_{oTD} = 15 (4–7 mice per donor). Metabolite abundances were median-normalized and plotted based on the Z-score from purple for highly abundant metabolites, to green, for metabolites detected in low levels.
(G–I) Median-normalized concentrations of (G) 5-aminovaleric acid, (H) taurine, (I) 3-aminoisobutyric acid, and (J) the isoflavones daidzein and genistein in colon contents. Data point color denotes donor. \( N_{oASD}=20, N_{oTD}=15 \) (4–7 mice per donor). Bar graphs denote mean and S.E.M. p-values were calculated using the maximum likelihood test of a mixed effect linear model. oTD and oASD are offspring of recipient mice. See also Figure S5 and Table S3.
Figure 5. Metagenomic analysis corroborates amino acid metabolism is deficient in oASD mice. 

(A) Putative bacterial contributors to variation in amino acids and other metabolites identified by a MIMOSA analysis, separated by their mechanism of action (synthesis/production, degradation/utilization, or both), and based on GC-MS (top) and NMR (bottom) metabolomic analysis and metagenomic analysis of colon contents in oASD mice.

(B) Differentially abundant KEGG orthologs involved in amino acid metabolism from HUMAnN2 by limma-voom analysis. Fold change and p-values are presented for significantly different pathways.

(C–E) Taurine production in oASD mice is deficient. (C) possible sources of taurine and KEGG orthologs involved. (D) abundance of K01442 and (E) K01580 copies in oTD and oASD mice quantified by HUMAnN2. Differences in Means were analyzed by a Kruskal-Wallis test.

(F–I) Pathways providing substrates for Stickland fermentation to produce 5AV are deficient in oASD mice. (F) pathways upstream to 5AV production and KEGG orthologs involved. (G) abundance of hypD (by ShortBRED) and the abundance of (H) K13821 and (I) K00286 copies in oTD and oASD mice quantified by HUMAnN2. Differences in Means were analyzed by a Kruskal-Wallis test.
See also Figure S5.
Figure 6. Microbial metabolites impact behaviors and brain physiology in the BTBR mouse model.

(A) Spearman’s rank correlation between discrete metabolites and male mouse behavior (see Figure 1). Benjamini-Hochberg adjusted p-values for significant (α ≤ 0.05) correlations are noted. Color scale denotes Spearman’s ρ from purple (positive correlation) to green (negative correlation).

(B) Targeted metabolomics for 5A V and taurine in E18.5 dams orally administered metabolites at 10mM in drinking water from E0.5 and on. Normalized concentrations of 5A V and taurine in dam’s colon contents, serum, amniotic fluid, and fetal brains were measured. Group differences were tested by Kruskal-Wallis test, Dunn post-hoc, and Holm correction for multiple comparisons. N=3–4 dams per group.

(C–E) 5A V and taurine ameliorate ASD-related behavioral deficits in the BTBR mouse model for ASD. Groups of mice were orally administered with either 10 mM taurine or 5A V in drinking water (ad libitum) before mating, and throughout their lifetime. Offspring were tested by (C) marble burying, (D) direct social interaction, and (E) open field tests, and compared to untreated vehicle controls. Results are aggregated from three independent
experiments. $N_{\text{Control}}= 42$, $N_{5AV}= 52$, $N_{\text{Taurine}}= 33$. Hypothesis on differences in means were tested by one-way ANOVA on trimmed means (10%) and subsequent post-hoc tests.

(F) Amplitude and frequency of mEPSCs in pyramidal neurons in the L5 of the mPFC in acute slices from 8–12 week old BTBR mice treated with 5AV, Taurine, or control from pregnancy to adulthood. tested by 1-way ANOVA on trimmed means (10%) and subsequent post-hoc tests. $N_{\text{Control}} = 21$ cells in 5 mice, $N_{5AV} = 18$ cells in 3 mice, $N_{\text{Taurine}} = 20$ cells in 4 mice.

(G) Amplitude and frequency of mIPSCs in pyramidal neurons in the L5 of the mPFC in acute slices from 8–12 week old BTBR mice treated with 5AV, Taurine, or control from pregnancy to adulthood. tested by one-way ANOVA on trimmed means (10%) and subsequent post-hoc tests. $N_{\text{Control}} = 21$ cells in 4 mice, $N_{5AV} = 17$ cells in 3 mice, $N_{\text{Taurine}} = 20$ cells in 4 mice.

(H) Excitability of pyramidal neurons in the L5 of the mPFC in acute slices from BTBR mice treated with 5AV, Taurine, or control, in response to step-wise injection of current, as measured by the number of action potential spikes. Two-way ANOVA and Dunnett’s post-hoc. * $P < 0.05$, ** $P<0.01$.

See also Figure S6.